Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
02/2000
02/22/2000US6028069 For treating or preventing arrhythmias, angina pectoris or infarcts comprising administering effective dosage to patient
02/22/2000US6028051 Administering single dose of lysostaphin analogue and lysostaphin for treating endocarditis, bacterimia, kidney infection, lung infection, skin infection, bone infection, burn wound infections, infection of prosthetic devices
02/22/2000US6027921 Chimeric proteins for use in transport of a selected substance into cells and DNA encoding chimeric proteins
02/22/2000US6027919 BMP-12 and BMP-13 proteins and DNA encoding them
02/22/2000US6027711 Structurally determined metallo-constructs and applications
02/22/2000CA2170607C Difluoro statone antiviral analogs
02/22/2000CA2157248C Crystalline form of dihydro-2, 3 benzodiazepine derivative
02/21/2000CA2280596A1 New indan-1-ol derivatives, their preparation method, and pharmaceutical compositions containing them
02/18/2000CA2280455A1 The use of aryl-cyclohexylamine derivatives against cns disorders
02/17/2000WO2000008202A2 3-methylidenyl-2-indolinone modulators of protein kinase
02/17/2000WO2000008193A2 Latency-active regulatory sequences of herpesviruses and latency-inactive herpesvirus for gene transfer
02/17/2000WO2000008179A1 Ikr-1 and ikr-2, protein kinases which are related to the i kappa b kinases
02/17/2000WO2000008177A2 Death associated kinase containing ankyrin repeats (dakar)
02/17/2000WO2000008141A2 Short oligonucleotides for the inhibition of vegf expression
02/17/2000WO2000008140A2 Antisense oligonucleotides for the inhibition of vegf expression
02/17/2000WO2000008130A2 Method for preparing a cartilage cell suspension
02/17/2000WO2000008053A1 Novel g-protein coupled receptor protein and dna thereof
02/17/2000WO2000008046A1 Monocyclic compounds having nk-2 antagonist action and compositions containing them
02/17/2000WO2000008042A1 Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
02/17/2000WO2000008033A1 Water soluble prodrugs of hindered alcohols or phenols
02/17/2000WO2000008031A1 Novel phospholipids with unsaturated alkyl and acyl chains
02/17/2000WO2000008024A1 Substituted imidazo[1,2a]azines as selective inhibotors of cox-2
02/17/2000WO2000008007A2 Cyclopentabenzofuran derivatives and their use
02/17/2000WO2000008006A2 Piperidine and piperazine derivatives, process for their preparation and pharmaceutical compounds containing them
02/17/2000WO2000008001A1 Substituted isoxazole as estrogen receptor modulators
02/17/2000WO2000007997A1 IMIDAZOLES AND RELATED COMPOUNDS AS α1A AGONISTS
02/17/2000WO2000007995A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION
02/17/2000WO2000007994A1 Novel bi- and tri-cyclic aza compounds and their uses
02/17/2000WO2000007991A1 Amide derivatives useful as inhibitors of the production of cytokines
02/17/2000WO2000007987A1 Crystalline forms of osanetant
02/17/2000WO2000007986A1 Novel 2,3,3a,4,9,9a hexahydro-8-hydroxy-1h-benz[f]indoles, a method for the production thereof, and their use as medicaments
02/17/2000WO2000007980A1 Amide derivatives which are useful as cytokine inhibitors
02/17/2000WO2000007629A2 Peg-urate oxidase conjugates and use thereof
02/17/2000WO2000007624A2 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix
02/17/2000WO2000007618A2 Anti-apoptotic compositions comprising the r1 subunit of herpes simplex virus ribonucleotide reductase or its n-terminal portion; and uses thereof
02/17/2000WO2000007617A1 Use of glp-1 and analogues for preventing type ii diabetes
02/17/2000WO2000007616A2 Use of novel agents inducing cell death in synergy with interferons
02/17/2000WO2000007609A1 Peptide antagonists of zonulin and methods for use of the same
02/17/2000WO2000007606A2 Methods for increasing the solubility of nutritional materials using probiotic lactic acid-producing bacteria
02/17/2000WO2000007598A1 Use of a nk-1 receptor antagonist for treating or preventing abnormal bone resorption
02/17/2000WO2000007591A1 INDOLE sPLA2 INHIBITORS
02/17/2000WO2000007590A1 INDOLE sPLA2 INHIBITORS
02/17/2000WO2000007581A2 Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid
02/17/2000WO2000007577A2 Phosphatidylcholine as a medicament for the protection of mucosa
02/17/2000WO2000007576A2 INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE
02/17/2000WO2000007567A1 Medicinal aerosol formulations
02/17/2000WO2000007545A2 Apoptosis proteins
02/17/2000WO1999065942A8 Cyclic somatostatin analogs
02/17/2000WO1999058691A3 Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
02/17/2000WO1999057241A9 Myelin basic protein peptides and uses thereof
02/17/2000WO1999056784A3 Inprovements in gene therapy using compositions comprising a polynucleotide and a nuclease inhibitor or interleukin-10
02/17/2000WO1999056763A9 Use of neglected target tissue antigens in modulation of immune responses
02/17/2000WO1999055859A3 Cd40-interacting and traf-interacting proteins
02/17/2000WO1999054310A3 New substituted amides, their production and their use
02/17/2000WO1999049909A9 Revascularization apparatus having coaxial channeling and injecting means
02/17/2000WO1999044596A3 Glycine transport inhibitors
02/17/2000DE19836697A1 New substituted 4-amino-2-aryl-pyrimidines, are soluble guanylate cyclase activators useful e.g. for treating atherosclerosis, hypertension, angina pectoris, thrombosis, asthma or diabetes
02/17/2000DE19836044A1 New 2-(hetero)aryl-alkanoic acid derivatives, useful as mixed endothelin receptor antagonists, e.g. for treating cardiac insufficiency, restenosis, hypertension or prostate cancer
02/17/2000CA2383623A1 3-methylidenyl-2-indolinone modulators of protein kinase
02/17/2000CA2339643A1 Methods for increasing the solubility of nutritional materials using probiotic lactic acid-producing bacteria
02/17/2000CA2339638A1 Monocyclic compounds having nk-2 antagonist action and compositions containing them
02/17/2000CA2339416A1 Short oligonucleotides for the inhibition of vegf expression
02/17/2000CA2339408A1 Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
02/17/2000CA2339368A1 Inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase
02/17/2000CA2339340A1 Antisense oligonucleotides for the inhibition of vegf expression
02/17/2000CA2339187A1 Substituted imidazo¬1,2a|azines as selective inhibitors of cox-2
02/17/2000CA2339146A1 Use of a nk-1 receptor antagonist for treating or preventing abnormal bone resorption
02/17/2000CA2339122A1 Novel bi- and tri-cyclic aza compounds and their uses
02/17/2000CA2339086A1 Dna replication- and repair-associated proteins
02/17/2000CA2339007A1 Crystalline forms of osanetant
02/17/2000CA2338944A1 Succinoylamino lactams as inhibitors of a.beta. protein production
02/17/2000CA2338855A1 Indole spla2 inhibitors
02/17/2000CA2338727A1 Indole spla2 inhibitors
02/17/2000CA2338594A1 Imidazoles and related compounds as .alpha.1a agonists
02/17/2000CA2338121A1 Amide derivatives useful as inhibitors of the production of cytokines
02/17/2000CA2338035A1 Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid
02/17/2000CA2337963A1 Latency-active regulatory sequences of herpesviruses and latency-inactive herpesvirus for gene transfer
02/17/2000CA2335648A1 A novel g protein-coupled receptor protein and its dna
02/17/2000CA2305680A1 Death associated kinase containing ankyrin repeats (dakar)
02/17/2000CA2305406A1 Pharmaceutical compounds
02/16/2000EP0979869A1 Short oligonucleotides for the inhibition of VEGF expression
02/16/2000EP0979822A1 Process for the preparation of 2-carbamoyl-pyridines
02/16/2000EP0979817A1 Leukotriene a 4? hydrolaze inhibitors
02/16/2000EP0979816A1 Hydroxamic acid derivatives, process for their preparation and pharmaceutical compositions containing them
02/16/2000EP0979292A2 Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety
02/16/2000EP0979280A1 Polynucleotides encoding a cd53-like transmembrane protein
02/16/2000EP0979276A1 Complement receptor type 1 (cr1)-like sequences
02/16/2000EP0979275A1 Novel human mago nashi protein
02/16/2000EP0979274A2 Human p24 vesicle proteins
02/16/2000EP0979245A1 Oligopeptidic inhibitors of elastases and methods of preparation thereof
02/16/2000EP0979240A1 Serine protease inhibitors
02/16/2000EP0979230A1 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
02/16/2000EP0979228A1 Novel cannabinoid receptor agonists
02/16/2000EP0979104A1 Sonodynamic therapy using an ultrasound sensitizer compound
02/16/2000EP0979098A1 Method of treating hyperprolactinemia and prolactinomas
02/16/2000EP0979094A2 Agent for enhancing the heart force
02/16/2000EP0979092A2 Allelic polygene diagnosis of reward deficiency syndrome and treatment
02/16/2000EP0979086A2 Method and composition for modulating amyloidosis
02/16/2000EP0979085A1 Treatment of eosinophil-associated pathologies, such as bronchial asthma, with synergistic combinations of glucocorticoids and a local anesthetics
02/16/2000EP0979084A1 Use of anabolic steroid derivatives in the treatment of chronic heart failure
1 ... 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 ... 1564